The long awaited global review on antimicrobial resistance by economist Lord Jim O’Neill has been published. It sets out an action plan to defeat superbugs with a huge awareness campaign and rapid diagnostics to be used before antibiotics are prescribed.

Bayer is deepening its involvement in CRISPR with a licensing agreement for genome editing patents. Irish partner ERS Genomics holds the rights to the CRISPR/Cas9 tech from Emmanuelle Charpentier, one of the inventors.

Hansa Medical, a Swedish biopharmaceutical company focusing on novel immunomodulatory enzymes, has appointed Henk Doude van Troostwijk as Vice President, Commercial Operations.

Molecular Devices®, market leader in microplate reader technology for over 25 years, has announced the launch of its SpectraMax® i3 Multi-Mode Detection Platform with SpectraMax® MiniMax® Imaging Cytometer.

Newly spun out company OxStem has raised £16.9m (€21.5m) to develop regenerative meds for the treatment of age-related disease. It is the largest financing for an Oxford spin-out – or any UK academic spin-out – to date.

Swiss Genentech partner AC Immune has raised CHF42.7m (€38.6m) in order to advance its therapeutic and diagnostic product pipeline in Alzheimer’s disease. The news follows a recently announced R&D collaboration with Biogen.

The Oligo PRO™ 96XT system provides fast, automated and economical size-based purity analysis of single stranded DNA and RNA oligonucleotides, and double stranded RNA interference (RNAi) products.

Belgian CRO and service provider Genea has appointed a new Chief Medical Officer. Jörn Balzer will be responsible for the clinical, safety and risk management in Genae’s research services.

Diabetes vaccine developer Diamyd Medical has a new CEO. From now on, Ulf Hannelius will lead the Stockholm-based company.

Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.